BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu L, Qiu C, Li D, Bai G, Liang J, Yang Q. MicroRNA-505 suppresses proliferation and invasion in hepatoma cells by directly targeting high-mobility group box 1. Life Sci. 2016;157:12-18. [PMID: 27259809 DOI: 10.1016/j.lfs.2016.05.039] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Guo Y, Xu X, Tang T, Sun L, Zhang X, Shen X, Li D, Wang L, Zhao L, Xie P. miR-505 inhibits replication of Borna disease virus 1 via inhibition of HMGB1-mediated autophagy. Journal of General Virology 2022;103. [DOI: 10.1099/jgv.0.001713] [Reference Citation Analysis]
2 Krkoška M, Nekvindová J, Nevědělová K, Zubáňová V, Radová L, Vondráček J, Herůdková J, Slabý O, Kiss I, Bohovicová L, Fabian P, Tylichová Z, Kala Z, Kysela P, Ostřížková L, Palička V, Hyršlová Vaculová A. Role of miR-653 and miR-29c in downregulation of CYP1A2 expression in hepatocellular carcinoma. Pharmacol Rep 2021. [PMID: 34780054 DOI: 10.1007/s43440-021-00338-9] [Reference Citation Analysis]
3 Lamberti MJ, Nigro A, Casolaro V, Rumie Vittar NB, Dal Col J. Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome. Cancers (Basel) 2021;13:2566. [PMID: 34073766 DOI: 10.3390/cancers13112566] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
4 Chen Y, Xie H, Xie T, Yang X, Pang Y, Ye S. Elevated Expression of PDZD11 Is Associated With Poor Prognosis and Immune Infiltrates in Hepatocellular Carcinoma. Front Genet 2021;12:669928. [PMID: 34093661 DOI: 10.3389/fgene.2021.669928] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Xu Z, Zhang D, Zhang Z, Luo W, Shi R, Yao J, Li D, Wang L, Liao B. MicroRNA-505, Suppressed by Oncogenic Long Non-coding RNA LINC01448, Acts as a Novel Suppressor of Glycolysis and Tumor Progression Through Inhibiting HK2 Expression in Pancreatic Cancer. Front Cell Dev Biol 2020;8:625056. [PMID: 33520999 DOI: 10.3389/fcell.2020.625056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chi X, Jiang Y, Chen Y, Lv L, Chen J, Yang F, Zhang X, Pan F, Cai Q. microR-505/heterogeneous nuclear ribonucleoprotein M inhibits hepatocellular carcinoma cell proliferation and induces cell apoptosis through the Wnt/β-catenin signaling pathway. Biomark Med 2020;14:981-96. [PMID: 32940078 DOI: 10.2217/bmm-2019-0511] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Cheng Z, Wang B, Zhang C. MicroRNA-505-3p inhibits development of glioma by targeting HMGB1 and regulating AKT expression. Oncol Lett 2020;20:1663-70. [PMID: 32724408 DOI: 10.3892/ol.2020.11714] [Reference Citation Analysis]
8 Zhao S, Lu L, Liu Q, Chen J, Yuan Q, Qiu S, Wang X. MiR-505 promotes M2 polarization in choroidal neovascularization model mice by targeting transmembrane protein 229B. Scand J Immunol 2019;90:e12832. [PMID: 31544253 DOI: 10.1111/sji.12832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Cahová M, Daňková H, Heczková M, Brátová M, Ďásková N, Baštová H, Gojda J, Wohl P. MicroRNAs as potential markers of parenteral nutrition associated liver disease in adult patients. Physiol Res 2019;68:681-8. [PMID: 31177800 DOI: 10.33549/physiolres.934103] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Kapora E, Feng S, Liu W, Sakhautdinova I, Gao B, Tan W. MicroRNA-505-5p functions as a tumor suppressor by targeting cyclin-dependent kinase 5 in cervical cancer. Biosci Rep 2019;39:BSR20191221. [PMID: 31266812 DOI: 10.1042/BSR20191221] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ling XH, Fu H, Chen ZY, Lu JM, Zhuo YJ, Chen JH, Zhong WD, Jia Z. miR‑505 suppresses prostate cancer progression by targeting NRCAM. Oncol Rep 2019;42:991-1004. [PMID: 31322225 DOI: 10.3892/or.2019.7231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
12 Ren L, Yao Y, Wang Y, Wang S. MiR-505 suppressed the growth of hepatocellular carcinoma cells via targeting IGF-1R. Biosci Rep 2019;39:BSR20182442. [PMID: 31160483 DOI: 10.1042/BSR20182442] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
13 Wang J, Liu H, Li M. Downregulation of miR-505 promotes cell proliferation, migration and invasion, and predicts poor prognosis in breast cancer. Oncol Lett 2019;18:247-54. [PMID: 31289494 DOI: 10.3892/ol.2019.10334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
14 Dang SC, Wang F, Qian XB, Abdul M, Naseer QA, Jin W, Hu R, Gu Q, Gu M. MicroRNA-505 suppresses gastric cancer cell proliferation and invasion by directly targeting Polo-like kinase-1. Onco Targets Ther 2019;12:795-803. [PMID: 30774367 DOI: 10.2147/OTT.S189521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Tang H, Lv W, Sun W, Bi Q, Hao Y. miR‑505 inhibits cell growth and EMT by targeting MAP3K3 through the AKT‑NFκB pathway in NSCLC cells. Int J Mol Med 2019;43:1203-16. [PMID: 30628663 DOI: 10.3892/ijmm.2018.4041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
16 Schoen C, Glennon JC, Abghari S, Bloemen M, Aschrafi A, Carels CEL, Von den Hoff JW. Differential microRNA expression in cultured palatal fibroblasts from infants with cleft palate and controls. Eur J Orthod 2018;40:90-6. [PMID: 28486694 DOI: 10.1093/ejo/cjx034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
17 Zhang C, Yang X, Fu C, Liu X. Combination with TMZ and miR-505 inhibits the development of glioblastoma by regulating the WNT7B/Wnt/β-catenin signaling pathway. Gene 2018;672:172-9. [DOI: 10.1016/j.gene.2018.06.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
18 Zheng WJ, Yao M, Fang M, Wang L, Dong ZZ, Yao DF. Abnormal expression of HMGB-3 is significantly associated with malignant transformation of hepatocytes. World J Gastroenterol 2018; 24(32): 3650-3662 [PMID: 30166860 DOI: 10.3748/wjg.v24.i32.3650] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
19 Lu L, Zhang D, Xu Y, Bai G, Lv Y, Liang J. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1. Biomed Pharmacother 2018;104:613-21. [PMID: 29803174 DOI: 10.1016/j.biopha.2018.05.087] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
20 Chen Y, Bian L, Zhang Y. MiR-505 mediates methotrexate resistance in colorectal cancer by targeting RASSF8. Journal of Pharmacy and Pharmacology 2018;70:937-51. [DOI: 10.1111/jphp.12913] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
21 Lin CW, Chou YE, Yeh CM, Yang SF, Chuang CY, Liu YF. A functional variant at the miRNA binding site in HMGB1 gene is associated with risk of oral squamous cell carcinoma. Oncotarget 2017;8:34630-42. [PMID: 28423715 DOI: 10.18632/oncotarget.16120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
22 Liu J, Xiao Y, Wu X, Jiang L, Yang S, Ding Z, Fang Z, Hua H, Kirby MS, Shou J. A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis. BMC Genomics 2018;19:188. [PMID: 29523084 DOI: 10.1186/s12864-018-4575-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
23 Yan J, Ying S, Cai X. MicroRNA-Mediated Regulation of HMGB1 in Human Hepatocellular Carcinoma. Biomed Res Int 2018;2018:2754941. [PMID: 29651425 DOI: 10.1155/2018/2754941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
24 Liu YJ, Li W, Chang F, Liu JN, Lin JX, Chen DX. MicroRNA-505 is downregulated in human osteosarcoma and regulates cell proliferation, migration and invasion. Oncol Rep 2018;39:491-500. [PMID: 29251324 DOI: 10.3892/or.2017.6142] [Cited by in Crossref: 6] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
25 Mudduluru G, Ilm K, Fuchs S, Stein U. Epigenetic silencing of miR-520c leads to induced S100A4 expression and its mediated colorectal cancer progression. Oncotarget 2017;8:21081-94. [PMID: 28423501 DOI: 10.18632/oncotarget.15499] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
26 Guo Y, Chen L, Sun C, Yu C. MicroRNA-500a promotes migration and invasion in hepatocellular carcinoma by activating the Wnt/β-catenin signaling pathway. Biomed Pharmacother 2017;91:13-20. [PMID: 28437633 DOI: 10.1016/j.biopha.2017.04.018] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
27 Yao T, Chen Q, Fu L, Guo J. Circular RNAs: Biogenesis, properties, roles, and their relationships with liver diseases: Circular RNAs and liver diseases. Hepatol Res 2017;47:497-504. [DOI: 10.1111/hepr.12871] [Cited by in Crossref: 56] [Cited by in F6Publishing: 74] [Article Influence: 11.2] [Reference Citation Analysis]